GEV Research Update — September 24, 2026
Updated Thesis
GE Vernova is an energy equipment and infrastructure enterprise spanning Power (gas, nuclear, hydro, steam), Wind (offshore and onshore turbines), and Electrification (grid, power conversion, solar and storage), with 78,000 employees and a Cambridge, Massachusetts headquarters. The business quality is high on the strength of an installed base that generates roughly 25% of the world's electricity, a reported backlog near $200 billion, and a CEO who has said the company will be mostly sold out through 2030, which supports pricing power and multi-year revenue visibility in gas turbines and grid equipment. Fundamentals are inflecting: revenue grew 21.9% and earnings grew 30.0% in the most recent quarter, ROE is 83.4%, and free cash flow per share is $46.41, though TTM operating margin of 4.4% and gross margin of 20.2% show the earnings base is still thin and the 23.0% TTM net margin is flattered by a $3.992 billion pre-tax Prolec remeasurement gain.
The investment grade as of this refresh is B — solid business quality. A-tier business, C-tier valuation on historical multiples but undervalued versus blended fair value.
Grade Change
In this research cycle, the investment grade for GE Vernova Inc. moved from A- to B. A-tier business, C-tier valuation on historical multiples but undervalued versus blended fair value.
Key Metrics at a Glance
- Revenue growth: +21.9% year over year
- Net margin: 23.0%
- Fair value upside: +35.4% to our estimate of $1289
Current price: $951.82
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. GE Vernova Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full GEV research →](/stocks/GEV)